VEGF-C

We have just published our latest review about the role of KLK3 as an activator of VEGF-C and VEGF-D in prostate cancer. Prostate cancer is one of the most common cancers in males. It is not a question whether you will get it but only when.

Our opinion piece in Science Signaling was published. It discusses the results by Kataru et al., and how they relate to the continuing (re)search for a lymphedema drug after the discontinuation of the clinical trials with Lymfactin.

Vascular endothelial growth factor-C (VEGF-C) has been originally described as the primary growth factor for the lymphatic system.